Evidence map›Paper›PMID 8006584›Full record

ArticleThe Journal of experimental medicine1994

Interleukin 2 receptor gamma chain expression on resting and activated lymphoid cells.

T Nakarai, M J Robertson, M Streuli, Z Wu, T L Ciardelli, K A Smith, J Ritz

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of experimental medicine, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 123 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Family-Based Next-Generation Sequencing Study Identifies anOmics : a journal of integrative biology · 2019
    Article
  8. CD4Frontiers in immunology · 2019
    Article
  9. Article
  10. The common γ-chain cytokine receptor: tricks-and-treats for T cells.Cellular and molecular life sciences : CMLS · 2016
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Potent induction of long-term CD8+ T cell memory by short-term IL-4 exposure during T cell receptor stimulation.Proceedings of the National Academy of Sciences of the United States of America · 2000
    Article
  17. Article
  18. Article
  19. Regulatory dysfunction of the interleukin-2 receptor during HIV infection and the impact of triple combination therapy.Proceedings of the National Academy of Sciences of the United States of America · 1998
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

T NakaraiDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts 02115.
M J Robertson
M Streuli
Z Wu
T L Ciardelli
K A Smith
J Ritz
Dana-Farber Cancer Institute · US

Funding

REGULATION OF HUMAN NK CELL FUNCTIONR01CA041619 · NCI · DANA-FARBER CANCER INSTITUTE · PI RITZ, JEROME · 1986 to 2001
$637k
DESIGN OF MULTIMERIC INTERLEUKIN-2 RECEPTOR ECTODOMAINSR01AI034331 · NIAID · DARTMOUTH COLLEGE · PI CIARDELLI, THOMAS L · 1994 to 2000
$208k
NCI NIH HHS CA-41619NIAID NIH HHS AI-34331
6 · The paper itself

Abstract

The interleukin 2 receptor (IL-2R) is known to be comprised of at least three genetically distinct subunits termed alpha, beta, and gamma. These chains can be expressed individually or in various combinations resulting in distinct receptors with different affinities for IL-2. In contrast to alpha and beta, the cell surface expression of the gamma chain protein previously has not been well-characterized. To examine cell surface expression of IL-2R gamma on hematopoietic cells, we developed two new monoclonal antibodies (mAbs) specific for this protein. Both 1A11 (immunoglobulin [IgG1]) and 3G11 (IgM) specifically reacted with murine cells transfected with IL-2R gamma cDNA, and immunoprecipitation studies indicated that both antibodies precipitated a protein of approximately 62-65 kD. Scatchard analysis of IL-2 binding to murine cells transfected with cDNA-encoding combinations of IL-2R components demonstrated that neither beta nor gamma chain bind IL-2 with measurable affinity, but coexpression of both beta and gamma is sufficient to form an intermediate affinity receptor. In the absence of gamma chain, beta chain interacts with alpha chain to form a "pseudo-high" affinity receptor. In contrast, gamma chain does not appear capable of interacting with alpha in the absence of beta chain. Thus, gamma chain appears to interact only with beta, but beta chain is capable of interacting with both alpha and gamma. Using the newly developed mAbs to examine cell surface expression by immunofluorescence, resting T cells were found to express low levels of gamma chain without detectable alpha or beta. Early after mitogen stimulation, T cells expressed higher levels of alpha, beta, and gamma. However, at later time points, T cells expressed alpha and gamma in marked excess over beta. Thus, formation of high affinity IL-2R on activated T cells was primarily limited by beta chain expression. In contrast, resting natural killer (NK) cells constitutively expressed IL-2R beta without detectable alpha or gamma. After activation with either IL-2 or IL-12, expression of both alpha and gamma transiently increased and then returned to very low levels. Expression of functional IL-2R on resting and activated NK cells, therefore, appeared to be primarily limited by the expression of gamma chain. IL-2 binding studies with resting NK cells confirmed the results of immunofluorescence studies indicating the presence of very low numbers of intermediate affinity (beta gamma) receptors for IL-2 on these cells.(ABSTRACT TRUNCATED AT 400 WORDS)

Indexed as

Lymphocyte ActivationAnimalsAntibodies, MonoclonalBase SequenceCell LineHumansInterleukin-2Killer Cells, NaturalLymphocytesMiceMice, Inbred BALB CMolecular Sequence DataReceptors, Interleukin-2TransfectionAntibodies, MonoclonalInterleukin-2Receptors, Interleukin-2

Identifiers

PMID8006584
PMCPMC2191535
OpenAlexW2091217693

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.